Royalty Report: Drugs, Cancer, Biotechnology – Collection: 28774

License Grant

The Singapore Licensor grants to Licensee on a worldwide basis an exclusive royalty-bearing License to the Cell-in-a-Box® Trademark and its Associated Technology, with the right to subLicense in accordance.

License Property

Cell-in-a-Box® registered trademark No. 85307295

The Technology utilizes a cellulose-based live cell encapsulation technology, referred to  as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

The Licensed rights enable Licensee to develop the use of encapsulated products to obtain a Biologics License Application, marketing approval, or its equivalent in other territories and to eventually sell and offer for sale the Products or otherwise use the Licensed Rights on a worldwide basis as described and provided for within the Scope of this Agreement.

Licensor has developed a unique and versatile cell encapsulation technology using cellulose sulphate and derivatives that can be applied to a wide range of applications – Cell-in-a-Box® Trademark and its Associated Technology.

Living cell encapsulation or the Cell-in-a-Box® technology enables living cells to be used as a miniature factory in which cells can be grown and maintained, or desired components can be created or converted for treatment of diseases or isolating products for subsequent marketing.
One of the key uses of our technology is in the treatment of solid tumors where the ability to release the active agent directly at the source of the disease facilitates localized or systemic treatment as needed, thus having the value of increasing efficacy as the treatment agent is delivered directly to the critical site. Increased efficacy can also allow for lower dosages, thereby reducing side effects. The technology also holds great potential for the treatment of systemic diseases, including but not limited to diabetes.

Field of Use

The Licensee has interest in developing therapies for the treatment of diabetes with genetically modified or non-modified non-stem cell lines and IPS stem cells specifically designed to produce insulin or other critical components for the treatment of diabetes, to research, have made by Licensor, use in clinical trials, obtain market approval, market and sell products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology world-wide.

License Grant

Licensor, a Singapore corporation, hereby grants to Licensee on an exclusive worldwide royalty-bearing license to use the Cell-in-a-Box® Trademark and its Associated Technology with genetically modified non-stem cell lines which are designed to activate members of the cannabinoid family of molecules derived from Cannabis ('Cannabinoids') with the right to sublicense in accordance of this Agreement.  This license is granted to conduct research; have made by Licensor; use in preclinical studies and clinical trials; obtain Marketing Approval; and market and sell Products and treatments utilizing the Cell-in-a-Box® Trademark and its Associated Technology with Cannabinoids.

License Property

Licensor has developed a unique and versatile cell encapsulation technology using cellulose sulphate and derivatives that can be applied to a wide range of applications

'Cell-in-a-Box® Trademark and its Associated Technology' refers to United States registered trademark No. 85307295.

'Associated Technology' shall mean technologies marketed under the Cell-in-a-Box® registered trademark which enable encapsulation of live eukaryotic cells placed in a polymer where one constituent of the encapsulation material is cellulose sulphate or a derivative thereof and shall include any derivative or further development of these technologies.

Field of Use

Licensee has interest in developing therapies involving Cannabis, including the activation of Cannabinoids (defined below) for the treatment of diseases and related symptoms.

Licensee has interest in developing therapies involving Cannabis, including the activation of Cannabinoids for the treatment of diseases and related symptoms including the treatment of all diseases and medical conditions, including, but not limited to, pain, diabetes, cancer, other oxidation-associated diseases and all forms of mental illness.

License Grant

The Third Addendum and the Clarification Agreement provide the company with an exclusive world-wide license, with a right to sublicense, to use the Cell-in-a-Box® technology for the development of treatments for cancer and use of the Cell-in-a-Box® trademark and its associated technology using genetically modified HEK293 cells overexpressing the cytochrome P450 2B1 gene that are encapsulated using the licensed technology.

License Property

The Technology utilizes a cellulose-based live cell encapsulation technology, referred to  as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

The Cell-in-a-Box® technology, is a means to protect, isolate, store and transport living cells.
Bac-in-a-Box involves the technology which allows living cells to be encapsulated into bio-inert polymer beads. This technology allows both living eukaryotic (e.g. stem cells) and bacterial cells (e.g. probiotics) to be encapsulated in order to protect, store, isolate and transport them.

Field of Use

This agreement pertains to the medical drug industry relating to treatments for cancer.

License Grant

Licensors (of Denmark and Germany) hereby grant to Liechtenstein Licensee the non-exclusive irrevocable royalty-bearing, licence, with the right to sublicense, under the Licensed Patent Rights to further develop, make, have made (including services under contract for Licensee or sub-licensee, by Contract Manufacturing Organizations, Contract Research Organisations, Consultants, Logistics Companies or others), obtain marketing approval, sell and offer for sale the Licensed Product or otherwise use the Licensed Patent Rights in the Territory within the Field of this Agreement.

License Property

6,776,985 – Encapsulated cells producing viral particles
6,540,995 – Encapsulated cells producing cytochrome P450
6,893,634 – Encapsulated cells producing cytochrome P450

Licensors are a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.

Field of Use

Field of this Agreement shall mean the development, manufacture, sale and/or distribution of Licensed Products or other use based on the Licensed Patent Rights and Clinical Data directed to encapsulated cells producing viral particles and encapsulated cells expressing biomolecules.

Cell encapsulation technology is for use in oncology and diabetes.

The Licensee is utilizing a cellulose-based live cell encapsulation technology, referred to as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

License Grant

Liechtenstein Licensee was granted a non-exclusive license to, in particular, further develop, make, have made (including services under contract for Licensee or sub-licensee, by Contract Manufacturing Organizations, Contract Research Organisations, Consultants, Logistics Companies or others), obtain marketing approval, sell and offer for sale the Licensed Product or otherwise use the Licensed Patent Rights in the Territory within the Field of this Agreement.

This Amended License Agreement shall be changed from a non-exclusive into an exclusive license and the royalty rate shall be increased for each Licensed Product sold by Licensee and/or its Affiliates and/or its sub-licensees to a buyer.  LIcensee and Dutch Licensor also want to amend said License Agreement to make clear that the license will survive as a license granted by one of the Licensors if the other Licensor rejects performance under this Agreement due to any actions or declarations of insolvency.

License Property

6,776,985 – Encapsulated cells producing viral particles
6,540,995 – Encapsulated cells producing cytochrome P450
6,893,634 – Encapsulated cells producing cytochrome P450

Licensors are a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.

Field of Use

Field of this Agreement shall mean the development, manufacture, sale and/or distribution of Licensed Products or other use based on the Licensed Patent Rights and Clinical Data directed to encapsulated cells producing viral particles and encapsulated cells expressing biomolecules.

Cell encapsulation technology is for use in oncology and diabetes.

The Licensee is utilizing a cellulose-based live cell encapsulation technology, referred to as “Cell in-a-Box®,” to develop treatments for pancreatic cancer, breast cancer, brain cancer and diabetes.

License Grant

The Company acquired from the Australian University an exclusive, worldwide license to use genetically modified human cells.  In addition, the Company obtained the non-exclusive worldwide rights to “know-how” associated with the Melligen cells.

License Property

The Melligen Cells have been modified to produce, store and release insulin “on demand” in response to the blood glucose in their surroundings.

Field of Use

The Company intends to use the Melligen cells, after they have been encapsulated using the Cell-in-a-Box® technology, as a treatment for insulin-dependent diabetes.